1. Home
  2. AGIO vs GILT Comparison

AGIO vs GILT Comparison

Compare AGIO & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.65

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Gilat Satellite Networks Ltd.

GILT

Gilat Satellite Networks Ltd.

HOLD

Current Price

$18.51

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
GILT
Founded
2007
1987
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2013
1993

Fundamental Metrics

Financial Performance
Metric
AGIO
GILT
Price
$28.65
$18.51
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$36.25
$16.00
AVG Volume (30 Days)
1.3M
783.2K
Earning Date
02-12-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.22
EPS
N/A
0.41
Revenue
$44,791,000.00
$392,826,000.00
Revenue This Year
$27.83
$49.48
Revenue Next Year
$134.79
$13.61
P/E Ratio
N/A
$44.65
Revenue Growth
36.26
29.68
52 Week Low
$22.24
$5.30
52 Week High
$46.00
$18.45

Technical Indicators

Market Signals
Indicator
AGIO
GILT
Relative Strength Index (RSI) 52.75 81.07
Support Level $26.25 $16.87
Resistance Level $28.87 $18.39
Average True Range (ATR) 1.09 0.93
MACD 0.25 0.27
Stochastic Oscillator 74.29 99.15

Price Performance

Historical Comparison
AGIO
GILT

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About GILT Gilat Satellite Networks Ltd.

Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.

Share on Social Networks: